Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Norepinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.51 |
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.51 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.51 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.51 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.47 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.47 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | BLM | P54132 | 6/20 | 0.52 |
| ▸ | RECQL | P46063 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | THPO | P40225 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norepinephrine SCHEMBL17223916 | 0.87 | BLM (0.68) | TDP1KDM4EBLMRECQLMAPT | |
| Dopamine SCHEMBL28310234 | 0.86 | KDM4E (0.58) | TDP1KDM4EBLMRECQLMAPT | |
| Dopamine SCHEMBL524895 | 0.86 | KDM4E (0.58) | TDP1KDM4EBLMRECQLMAPT | |
| Norepinephrine SCHEMBL5026812 | 0.83 | BLM (0.68) | TDP1KDM4EBLMRECQLMAPT | |
| Tyrosine SCHEMBL5610789 | 0.81 | KDM4E (0.56) | TDP1KDM4EBLMRECQLMAPT | |
| Levodopa SCHEMBL9349770 | 0.80 | KDM4E (0.59) | TDP1KDM4EBLMRECQLMAPT | |
| Dopamine SCHEMBL3689353 | 0.80 | KDM4E (0.68) | TDP1KDM4EBLMRECQLMAPT | |
| Dopamine SCHEMBL20696071 | 0.80 | KDM4E (0.68) | TDP1KDM4EBLMRECQLMAPT | |
| Norepinephrine SCHEMBL632724 | 0.80 | MAPT (0.74) | TDP1KDM4EBLMRECQLMAPT | |
| Dopamine SCHEMBL10617780 | 0.78 | NFKB1 (0.49) | TDP1KDM4EBLMRECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212055-A4 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | REVAAX PHARMACEUTICALS LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2002064087-A2 | NEUROTHERAPEUTIC USE OF CARBOXYPEPTIDASE INHIBITORS | REVAAX PHARMACEUTICALS, LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1212055-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | Revaax Pharmaceuticals LLC (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001012184-A1 | NEUROTHERAPEUTIC COMPOSITION AND METHOD | REVAAX PHARMACEUTICALS, LLC (US) | 2001-02-22 | — | — | WO | disclosed |